Immuno-Oncology

Sipuleucel-T was the 1st  therapeutic vaccine approved by the FDA for prostate cancer in 2010. Similarly, ipilimumab was the first agent approved for metastatic melanoma in 2011. Since then, immunotherapies have become standard of care for many cancer types and has also become the front-line treatments for various cancer types. From September 2017 to September 2018, there was 67% increase in the number of active agents in immune- oncology pipeline, where, cell therapies had 113% increase in the number of active agents.

  • Track 1-1 Checkpoint inhibitors
  • Track 2-2 Monoclonal antibodies
  • Track 3-3 Vaccines
  • Track 4-4 Adoptive T-cell transfer
  • Track 5-5 Immunoediting
  • Track 6-6 CAR- T Cells
  • Track 7-7 Biomarkers

Related Conference of Oncology & Cancer